View Author
patient study treatment jtk -652 narlaprevir ana 773 hepatitis -652 virus infection group period concentration level hepg 2 cells genotype dosing activity placebo pharmacokinetic ritonavir hepatitis c patients plasma inhibitor response hcv-rna decline safety peg-ifn-a -2b effect protease pseudotype therapy hepatitis c cohort metabolite baseline hcv genotype 1 2000 mg group combination ribavirin peg-ifn-a figure sample phase value roche table change hepatology ifn-a serum hepatitis c virus 1600 mg groups hepatitis c infection virological response dose group entry trial administration hcv-rna levels neopterin inhibition hcv pseudotype virus liver 7 cells treatment-experienced patients 2000 mg >1.0 tlr 7 agonist fi ve patients regimen 1 log 10 treatment-na range increase fl u-like symptoms protein signi ifn-a concentrations
3 Most Recent Publications
|
Randomised clinical trial: Anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV
(Article)
Bergmann, J.F. Bruijne, J. Rahimy, M. Appleman, J.R. Freddo, J.L. Janssen, H.L.A. Reesink, H.W. Hotho, D.M. Knegt, R.J. de Boonstra, A. Weegink, C.J. Vliet, A.A. Wetering, J. van de Fletcher, S.P. Bauman, L.A. |
2011-08-01
|
|
Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients
(Article)
Bruijne, J. Bergmann, J.F. Lier, J.J. Vliet, A.A. Janssen, H.L.A. Knegt, R.J. de Reesink, H.W. Weegink, C.J. Molenkamp, R. Schinkel, J. Tong, X. Li, J. Treitel, M.A. Hughes, E.A. |
2010-11-01
|
|
Safety and antiviral activity of JTK-652: A novel HCV infection inhibitor
(Article)
Bruijne, J. Bergmann, J.F. Schinkel, J. Reesink, H.W. Janssen, H.L.A. Weegink, C.J. Nieuwkerk, C.M.J. van Knegt, R.J. de Komoda, Y. Rooij, J.J.V.D.W. de Vliet, A.A. Jansen, P.L.M. Molenkamp, R. |
2010-10-08
|
